Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074939 | 0.83 | L3MBTL1 (0.31) | — | |
| SCHEMBL14380221 | 0.82 | GRM4 (0.30) | GRM4 | |
| SCHEMBL19706408 | 0.80 | CES2 (0.33) | — | |
| SCHEMBL25530283 | 0.78 | — | — | |
| SCHEMBL19787617 | 0.76 | ALDH1A1 (0.33) | — | |
| SCHEMBL8273528 | 0.76 | GRM4 (0.32) | GRM4 | |
| SCHEMBL13262289 | 0.76 | ALDH1A1 (0.33) | GRM4 | |
| SCHEMBL9977958 | 0.76 | ALDH1A1 (0.38) | GRM4 | |
| SCHEMBL25979247 | 0.75 | KDM4E (0.43) | — | |
| SCHEMBL23950402 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | SREBF1, SREBF2, BPTF | GRM4 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.